SI20691B - Triciklični inhibitorji poli(ADP-riboza) polimeraz - Google Patents
Triciklični inhibitorji poli(ADP-riboza) polimeraz Download PDFInfo
- Publication number
- SI20691B SI20691B SI200020013A SI200020013A SI20691B SI 20691 B SI20691 B SI 20691B SI 200020013 A SI200020013 A SI 200020013A SI 200020013 A SI200020013 A SI 200020013A SI 20691 B SI20691 B SI 20691B
- Authority
- SI
- Slovenia
- Prior art keywords
- alkyl
- pharmaceutically acceptable
- compound
- acceptable salt
- aryl
- Prior art date
Links
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 title claims abstract 5
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 title 1
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 17
- 239000003814 drug Substances 0.000 claims abstract 7
- 206010019196 Head injury Diseases 0.000 claims abstract 2
- 206010028980 Neoplasm Diseases 0.000 claims abstract 2
- 208000006011 Stroke Diseases 0.000 claims abstract 2
- 230000004770 neurodegeneration Effects 0.000 claims abstract 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims abstract 2
- 150000003839 salts Chemical class 0.000 claims 13
- 125000000217 alkyl group Chemical group 0.000 claims 12
- 239000012453 solvate Substances 0.000 claims 12
- 125000003118 aryl group Chemical group 0.000 claims 11
- 125000003342 alkenyl group Chemical group 0.000 claims 10
- 125000000304 alkynyl group Chemical group 0.000 claims 10
- 229910052736 halogen Inorganic materials 0.000 claims 10
- 150000002367 halogens Chemical class 0.000 claims 10
- 125000000753 cycloalkyl group Chemical group 0.000 claims 9
- 125000001072 heteroaryl group Chemical group 0.000 claims 9
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 9
- 125000000547 substituted alkyl group Chemical group 0.000 claims 7
- 238000004519 manufacturing process Methods 0.000 claims 6
- 241000124008 Mammalia Species 0.000 claims 4
- 125000001424 substituent group Chemical group 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 239000004480 active ingredient Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- -1 hydroxy, nitro, amino Chemical group 0.000 claims 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 229940127397 Poly(ADP-Ribose) Polymerase Inhibitors Drugs 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000032677 cell aging Effects 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 230000018109 developmental process Effects 0.000 claims 1
- 230000004968 inflammatory condition Effects 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 230000009759 skin aging Effects 0.000 claims 1
- 125000003107 substituted aryl group Chemical group 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 claims 1
- 102000004357 Transferases Human genes 0.000 abstract 1
- 108090000992 Transferases Proteins 0.000 abstract 1
- 239000012830 cancer therapeutic Substances 0.000 abstract 1
- 229940127089 cytotoxic agent Drugs 0.000 abstract 1
- 239000002254 cytotoxic agent Substances 0.000 abstract 1
- 231100000599 cytotoxic agent Toxicity 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000005855 radiation Effects 0.000 abstract 1
- 0 CC*Cc1ccc(C(C)Nc2cccc3c2CCCCCCC3=*)cc1 Chemical compound CC*Cc1ccc(C(C)Nc2cccc3c2CCCCCCC3=*)cc1 0.000 description 12
- AYWSDKBPYSPJEM-KNTRCKAVSA-N C/C(/c1cc(CNC)ccc1)=C(/CCN1)\c(c(C)cc(C)c2)c2C1=O Chemical compound C/C(/c1cc(CNC)ccc1)=C(/CCN1)\c(c(C)cc(C)c2)c2C1=O AYWSDKBPYSPJEM-KNTRCKAVSA-N 0.000 description 1
- UBVLKAWZYCMFAS-UHFFFAOYSA-N CC(CCc1c(-c2cc(C(F)(F)I)cc(C(C)(F)F)c2)[nH]c2c1c1ccc2)C1=O Chemical compound CC(CCc1c(-c2cc(C(F)(F)I)cc(C(C)(F)F)c2)[nH]c2c1c1ccc2)C1=O UBVLKAWZYCMFAS-UHFFFAOYSA-N 0.000 description 1
- AOMBMTZORHTGAB-UHFFFAOYSA-N CCCc1c(-c(cc2)ccc2S(C)=O)[nH]c2cccc(C(C=N)=O)c12 Chemical compound CCCc1c(-c(cc2)ccc2S(C)=O)[nH]c2cccc(C(C=N)=O)c12 AOMBMTZORHTGAB-UHFFFAOYSA-N 0.000 description 1
- BRHQXUNXCURDTB-UHFFFAOYSA-N CNCc1cc(-c([nH]c2ccc3)c(CCN4)c2c3C4=O)ccc1 Chemical compound CNCc1cc(-c([nH]c2ccc3)c(CCN4)c2c3C4=O)ccc1 BRHQXUNXCURDTB-UHFFFAOYSA-N 0.000 description 1
- MRDWIBPBWIAABA-UHFFFAOYSA-N CSc(cc1)ccc1-c([nH]c1ccc2)c(CCN3)c1c2C3=O Chemical compound CSc(cc1)ccc1-c([nH]c1ccc2)c(CCN3)c1c2C3=O MRDWIBPBWIAABA-UHFFFAOYSA-N 0.000 description 1
- HIGZKNDJIPGYLX-UHFFFAOYSA-N O=C(CCCCc1c(-c(cccc2)c2Cl)[nH]2)c3c1c2ccc3 Chemical compound O=C(CCCCc1c(-c(cccc2)c2Cl)[nH]2)c3c1c2ccc3 HIGZKNDJIPGYLX-UHFFFAOYSA-N 0.000 description 1
- IBDSTXAFGGDXIU-UHFFFAOYSA-N O=C(CCCCc1c(-c2cc(C(F)(F)F)ccc2)[nH]2)c3c1c2ccc3 Chemical compound O=C(CCCCc1c(-c2cc(C(F)(F)F)ccc2)[nH]2)c3c1c2ccc3 IBDSTXAFGGDXIU-UHFFFAOYSA-N 0.000 description 1
- ZGTPDWCNOCXVRI-UHFFFAOYSA-N O=C(CCCCc1c(-c2cc3ccccc3[o]2)[nH]2)c3c1c2ccc3 Chemical compound O=C(CCCCc1c(-c2cc3ccccc3[o]2)[nH]2)c3c1c2ccc3 ZGTPDWCNOCXVRI-UHFFFAOYSA-N 0.000 description 1
- NULJFWUARDTONE-UHFFFAOYSA-N O=C(CCCc1c(C(CC2)=CC=C2C(F)(F)F)[nH]2)c3c1c2ccc3 Chemical compound O=C(CCCc1c(C(CC2)=CC=C2C(F)(F)F)[nH]2)c3c1c2ccc3 NULJFWUARDTONE-UHFFFAOYSA-N 0.000 description 1
- NMQLMBRYYSMDJX-UHFFFAOYSA-N O=C(CCCc1c(C(CC=C2)C=C2Cl)[nH]2)c3c1c2ccc3 Chemical compound O=C(CCCc1c(C(CC=C2)C=C2Cl)[nH]2)c3c1c2ccc3 NMQLMBRYYSMDJX-UHFFFAOYSA-N 0.000 description 1
- VNXWVXAZUCWHAU-UHFFFAOYSA-N O=C1NCCc2c(-c(ccc(F)c3)c3F)[nH]c3cccc1c23 Chemical compound O=C1NCCc2c(-c(ccc(F)c3)c3F)[nH]c3cccc1c23 VNXWVXAZUCWHAU-UHFFFAOYSA-N 0.000 description 1
- GNBUVWMGNHWWHX-UHFFFAOYSA-N O=C1NCCc2c(-c3cccc(CN4CCCCC4)c3)[nH]c3c2c1ccc3 Chemical compound O=C1NCCc2c(-c3cccc(CN4CCCCC4)c3)[nH]c3c2c1ccc3 GNBUVWMGNHWWHX-UHFFFAOYSA-N 0.000 description 1
- CCJPTCQYBNSURT-UHFFFAOYSA-N O=C1NCCc2c(-c3ccccc3)[nH]c3c2c1cc(Br)c3 Chemical compound O=C1NCCc2c(-c3ccccc3)[nH]c3c2c1cc(Br)c3 CCJPTCQYBNSURT-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/06—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/06—Peri-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11543199P | 1999-01-11 | 1999-01-11 | |
| PCT/US2000/000411 WO2000042040A1 (en) | 1999-01-11 | 2000-01-10 | Tricyclic inhibitors of poly(adp-ribose) polymerases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| SI20691A SI20691A (sl) | 2002-04-30 |
| SI20691B true SI20691B (sl) | 2008-10-31 |
Family
ID=22361361
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI200020013A SI20691B (sl) | 1999-01-11 | 2000-01-10 | Triciklični inhibitorji poli(ADP-riboza) polimeraz |
Country Status (39)
Families Citing this family (124)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6291425B1 (en) | 1999-09-01 | 2001-09-18 | Guilford Pharmaceuticals Inc. | Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage |
| EP1183259A2 (de) * | 1999-09-28 | 2002-03-06 | Basf Aktiengesellschaft | Azepinoindol-derivate, deren herstellung und anwendung |
| US6589725B1 (en) | 1999-10-25 | 2003-07-08 | Rigel Pharmaceuticals, Inc. | Tankyrase H, compositions involved in the cell cycle and methods of use |
| US6476048B1 (en) | 1999-12-07 | 2002-11-05 | Inotek Pharamaceuticals Corporation | Substituted phenanthridinones and methods of use thereof |
| US6531464B1 (en) | 1999-12-07 | 2003-03-11 | Inotek Pharmaceutical Corporation | Methods for the treatment of neurodegenerative disorders using substituted phenanthridinone derivatives |
| AU783393B2 (en) * | 2000-03-20 | 2005-10-20 | N-Gene Research Laboratories Inc. | Propenecarboxylic acid amidoxime derivatives, a process for the preparation thereof, and pharmaceutical compositions containing the same |
| US6534651B2 (en) | 2000-04-06 | 2003-03-18 | Inotek Pharmaceuticals Corp. | 7-Substituted isoindolinone inhibitors of inflammation and reperfusion injury and methods of use thereof |
| JP4323802B2 (ja) | 2000-12-01 | 2009-09-02 | エムジーアイ・ジーピー・インコーポレーテッド | 化合物およびその使用 |
| WO2002090334A1 (en) | 2001-05-08 | 2002-11-14 | Kudos Pharmaceuticals Limited | Isoquinolinone derivatives as parp inhibitors |
| AU2002331621B2 (en) | 2001-08-15 | 2008-06-05 | Icos Corporation | 2H-phthalazin-1-ones and methods for use thereof |
| US20030096833A1 (en) | 2001-08-31 | 2003-05-22 | Jagtap Prakash G. | Substituted ideno[1,2-c]isoquinoline derivatives and methods of use thereof |
| US6956035B2 (en) | 2001-08-31 | 2005-10-18 | Inotek Pharmaceuticals Corporation | Isoquinoline derivatives and methods of use thereof |
| WO2003051879A1 (en) * | 2001-12-14 | 2003-06-26 | Altana Pharma Ag | Known and novel 4,5-dihydro-imidazo[4,5,1-ij]quinolin-6-ones useful as poly(adp-ribose)polymerase inhibitors |
| DE60335359D1 (de) | 2002-04-30 | 2011-01-27 | Kudos Pharm Ltd | Phthalazinonderivate |
| JP3990718B2 (ja) | 2003-01-09 | 2007-10-17 | ファイザー・インク | キナーゼ阻害剤としてのジアゼピノインドール誘導体 |
| EP1603567A4 (en) | 2003-02-28 | 2006-10-18 | Inotek Pharmaceuticals Corp | TETRACYCLIC BENZAMIDE DERIVATIVES AND METHOD OF USE THEREOF |
| GB0305681D0 (en) | 2003-03-12 | 2003-04-16 | Kudos Pharm Ltd | Phthalazinone derivatives |
| US7449464B2 (en) | 2003-03-12 | 2008-11-11 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
| CA2520997A1 (en) * | 2003-03-31 | 2004-10-14 | Stacie Sara Canan-Koch | Salts of tricyclic inhibitors of poly(adp-ribose) polymerases |
| ES2396334T3 (es) * | 2003-05-28 | 2013-02-20 | Eisai Inc. | Compuestos, métodos y composiciones farmacéuticas para la inhibición de PARP |
| US7531530B2 (en) * | 2003-07-25 | 2009-05-12 | Cancer Research Technology Limited | Therapeutic compounds |
| GB0317466D0 (en) | 2003-07-25 | 2003-08-27 | Univ Sheffield | Use |
| PL2305221T3 (pl) | 2003-12-01 | 2015-11-30 | Kudos Pharm Ltd | Inhibitory naprawy uszkodzeń DNA w leczeniu raka |
| US20050228007A1 (en) | 2004-02-26 | 2005-10-13 | Prakash Jagtap | Isoquinoline derivatives and methods of use thereof |
| GB0419072D0 (en) | 2004-08-26 | 2004-09-29 | Kudos Pharm Ltd | Phthalazinone derivatives |
| PT1794163E (pt) * | 2004-09-22 | 2010-03-01 | Pfizer | Método para a preparação de inibidores de poli(adpribose)- polimerases |
| MX2007003314A (es) * | 2004-09-22 | 2007-08-06 | Pfizer | Combinaciones terapeuticas que comprenden inhibidor de poli(adp-ribosa)polimerasas. |
| ATE551345T1 (de) | 2004-09-22 | 2012-04-15 | Pfizer | Polymorphe formen des phosphatsalzes von 8-fluor- 2-ä4-ä(methylamino)methylüphenylü-1,3,4,5- tetrahydro-6h-azepinoä5,4,3-cdüindol-6-on |
| CN101133061B (zh) * | 2004-09-22 | 2011-09-07 | 辉瑞有限公司 | 8-氟-2-{4-[（甲基氨基）甲基]苯基}-1,3,4,5-四氢-6H-氮杂卓并[5,4,3-cd]吲哚-6-酮的磷酸盐的多晶型物和非晶物 |
| US7820668B2 (en) | 2005-01-19 | 2010-10-26 | Eisai Inc. | Diazabenzo[de]anthracen-3-one compounds and methods for inhibiting PARP |
| JP2008531562A (ja) | 2005-02-25 | 2008-08-14 | イノテック ファーマシューティカルズ コーポレイション | 四環アミノ化合物および四環カルボキサミド化合物およびこれらの使用法 |
| US7402596B2 (en) | 2005-03-24 | 2008-07-22 | Renovis, Inc. | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof |
| DE102005022111A1 (de) * | 2005-05-12 | 2006-11-16 | Siemens Ag | Verfahren zum Datenaustausch |
| WO2006137510A1 (ja) * | 2005-06-24 | 2006-12-28 | Ono Pharmaceutical Co., Ltd. | 脳血管障害時における出血低減剤 |
| MX2008000462A (es) | 2005-07-14 | 2008-03-10 | Irm Llc | Compuestos heterotetraciclicos como mimeticos de tpo. |
| ZA200800907B (en) | 2005-07-18 | 2010-04-28 | Bipar Sciences Inc | Treatment of cancer |
| CN101316592A (zh) | 2005-08-24 | 2008-12-03 | 伊诺泰克制药公司 | 茚并异喹啉酮类似物及其用法 |
| GB0521373D0 (en) | 2005-10-20 | 2005-11-30 | Kudos Pharm Ltd | Pthalazinone derivatives |
| EP1976515A2 (en) * | 2006-01-17 | 2008-10-08 | Abbott Laboratories | Combination therapy with parp inhibitors |
| TWI464148B (zh) | 2006-03-16 | 2014-12-11 | Evotec Us Inc | 作為ｐ２ｘ7調節劑之雙環雜芳基化合物與其用途 |
| US20080262062A1 (en) * | 2006-11-20 | 2008-10-23 | Bipar Sciences, Inc. | Method of treating diseases with parp inhibitors |
| CN101534836B (zh) | 2006-09-05 | 2011-09-28 | 彼帕科学公司 | Parp抑制剂在制备治疗肥胖症的药物中的用途 |
| WO2008030883A2 (en) | 2006-09-05 | 2008-03-13 | Bipar Sciences, Inc. | Treatment of cancer |
| KR20090115879A (ko) | 2007-02-28 | 2009-11-09 | 이노텍 파마슈티컬스 코포레이션 | 인데노이소퀴놀리논 유사체와 이의 이용 방법 |
| WO2008154129A1 (en) * | 2007-06-08 | 2008-12-18 | Bausch & Lomb Incorporated | Pharmaceutical compositions and method for treating, reducing, ameliorating, alleviating, or preventing dry eye |
| MX2010002749A (es) | 2007-09-14 | 2010-06-25 | Astrazeneca Ab | Derivados de ftalazinona. |
| ES2504690T3 (es) | 2007-10-03 | 2014-10-08 | Eisai Inc. | Compuestos inhibidores de PARP, composiciones y métodos de uso |
| US7732491B2 (en) | 2007-11-12 | 2010-06-08 | Bipar Sciences, Inc. | Treatment of breast cancer with a PARP inhibitor alone or in combination with anti-tumor agents |
| UY31603A1 (es) | 2008-01-23 | 2009-08-31 | Derivados de ftalazinona | |
| GB0804755D0 (en) | 2008-03-14 | 2008-04-16 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| CA2737400C (en) | 2008-10-07 | 2016-11-22 | Astrazeneca Uk Limited | Pharmaceutical formulation 514 |
| WO2011058367A2 (en) | 2009-11-13 | 2011-05-19 | Astrazeneca Ab | Diagnostic test for predicting responsiveness to treatment with poly(adp-ribose) polymerase (parp) inhibitor |
| KR100986820B1 (ko) * | 2010-01-27 | 2010-10-12 | (주)에코베이스 | 막힘방지형 고효율 산기장치 및 이를 이용한 수질정화장치 |
| EP4166558A1 (en) | 2010-02-12 | 2023-04-19 | Pfizer Inc. | Salts and polymorphs of 8-fluoro-2-{4- [(methylamino)methyl]phenyl}-1 ,3,4,5-tetrahydro-6h-azepino[5,4,3- cd]indol-6-one |
| JP5699223B2 (ja) | 2010-12-02 | 2015-04-08 | シャンハイ デュァ ノボ ファルマテック カンパニー リミテッド | 複素環誘導体、その合成法および医療用途 |
| MX2014008071A (es) | 2011-12-31 | 2015-07-06 | Beigene Ltd | Tetra o penta-piridoftalazinonas ciclicas fusionadas como inhibidores de poli(adenosin-difosfato-ribosa)polimerasas. |
| MX353578B (es) | 2011-12-31 | 2018-01-19 | Beigene Ltd | Dihidrodiazpinocarbazolonas tetra o penta-ciclicas fusionadas como inhibidores de poli (adp-ribosa) polimerasa (parp). |
| US9855261B2 (en) | 2012-11-08 | 2018-01-02 | Nippon Kayaku Kabushiki Kaisha | Polymeric compound having camptothecin compound and anti-cancer effect enhancer bound thereto, and use of same |
| CA2935857C (en) | 2014-01-05 | 2020-12-15 | Washington University | Radiolabeled tracers for poly (adp-ribose) polymerase-1 (parp-1), methods and uses therefor |
| CN103772395B (zh) * | 2014-01-23 | 2016-05-11 | 中国药科大学 | 一类具有parp抑制活性的化合物、其制备方法及用途 |
| SG11201610500WA (en) | 2014-06-17 | 2017-01-27 | Vertex Pharma | Method for treating cancer using a combination of chk1 and atr inhibitors |
| AU2015305696B2 (en) | 2014-08-22 | 2019-08-29 | Pharma& Schweiz Gmbh | High dosage strength tablets of rucaparib |
| CN105607772B (zh) * | 2014-11-13 | 2020-11-03 | 现代自动车株式会社 | 触摸输入装置以及包括该装置的车辆 |
| TW201702218A (zh) | 2014-12-12 | 2017-01-16 | 美國杰克森實驗室 | 關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法 |
| EP3265560B1 (en) | 2015-03-02 | 2021-12-08 | Sinai Health System | Homologous recombination factors |
| AU2016296905B2 (en) | 2015-07-23 | 2018-07-05 | Centre National De La Recherche Scientifique | Use of a combination of Dbait molecule and parp inhibitors to treat cancer |
| EA037366B1 (ru) | 2015-08-25 | 2021-03-18 | Бейджин, Лтд. | Способ получения ингибитора parp, кристаллические формы и их применения |
| AU2016331955B2 (en) | 2015-09-30 | 2022-07-21 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors |
| WO2017156350A1 (en) | 2016-03-09 | 2017-09-14 | K-Gen, Inc. | Methods of cancer treatment |
| CN107286166B (zh) * | 2016-04-11 | 2020-03-31 | 上海勋和医药科技有限公司 | 取代1，3，4，5-四氢-6h-吡咯并[4，3，2-ef][2]苯并氮杂-6-酮衍生物 |
| WO2018022851A1 (en) | 2016-07-28 | 2018-02-01 | Mitobridge, Inc. | Methods of treating acute kidney injury |
| CN110087730B (zh) | 2016-09-27 | 2023-03-28 | 百济神州(苏州)生物科技有限公司 | 使用包含parp抑制剂的组合产品治疗癌症 |
| JP6541635B2 (ja) * | 2016-10-28 | 2019-07-10 | ベイジーン リミテッド | Ｐａｒｐ阻害剤としての縮合四環式または縮合五環式ジヒドロジアゼピノカルバゾロン |
| RU2019114863A (ru) | 2016-11-02 | 2020-12-03 | Иммуноджен, Инк. | Комбинированное лечение конъюгатами антитело-лекарственное средство и ингибиторами parp |
| CN106854172B (zh) * | 2016-12-11 | 2019-04-19 | 山东轩德医药科技有限公司 | 一种6-氟-1h-吲哚-4-甲酸甲酯的制备方法 |
| WO2018122168A1 (en) | 2016-12-29 | 2018-07-05 | Bayer Pharma Aktiengesellschaft | Combinations of bub1 kinase and parp inhibitors |
| WO2018140377A1 (en) | 2017-01-24 | 2018-08-02 | Assia Chemical Industries Ltd. | Solid state forms of rucaparib and of rucaparib salts |
| CN106748958B (zh) * | 2017-01-25 | 2018-12-18 | 伦俊杰 | 一种Rucaparib中间体的制备方法 |
| CN115433187B (zh) | 2017-02-28 | 2023-10-27 | 百济神州(苏州)生物科技有限公司 | 稠合的四环或五环二氢二氮杂䓬并咔唑酮的盐的结晶形式组合物及其用途 |
| WO2018162439A1 (en) | 2017-03-08 | 2018-09-13 | Onxeo | New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule |
| JP7264489B2 (ja) | 2017-05-24 | 2023-04-25 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | イメージング及び放射線療法のための放射標識された蛍光性ｐａｒｐ阻害剤 |
| IT201700085789A1 (it) | 2017-07-26 | 2019-01-26 | Olon Spa | Metodo per la preparazione di rucaparib ad elevata purezza |
| WO2019023621A1 (en) | 2017-07-28 | 2019-01-31 | Yale University | ANTICANCER DRUGS AND METHODS OF MAKING AND USING THEM |
| CN109651377B (zh) * | 2017-10-12 | 2020-10-20 | 成都海创药业有限公司 | 一种治疗癌症的化合物及其用途 |
| CN109651376B (zh) * | 2017-10-12 | 2022-06-03 | 江苏创诺制药有限公司 | 一种氮杂卓并[5,4,3-cd]吲哚-6-酮化合物的合成方法 |
| EP3704124A1 (en) * | 2017-11-03 | 2020-09-09 | Sandoz AG | Crystalline salt of a tricyclic poly(adp-ribose) polymerase inhibitor |
| WO2019115000A1 (en) | 2017-12-15 | 2019-06-20 | Advitech Advisory And Technologies Sa | Process for the preparation of rucaparib and novel synthesis intermediates |
| WO2019130229A1 (en) | 2017-12-28 | 2019-07-04 | Mylan Laboratories Ltd | Methods and intermediates for preparing rucaparib |
| KR20200121800A (ko) | 2018-01-05 | 2020-10-26 | 싸이브렉사 1, 인크. | 산성 또는 저산소성 질환에 걸린 조직에 관련된 질환의 치료를 위한 화합물, 조성물 및 방법 |
| US10442813B2 (en) | 2018-01-30 | 2019-10-15 | RK Pharma Solutions LLC | Polymorphs of rucaparib camsylate and methods of making same |
| CN110229162B (zh) * | 2018-03-05 | 2020-08-11 | 新发药业有限公司 | 一种瑞卡帕布的简便制备方法 |
| CA3092779A1 (en) | 2018-03-13 | 2019-09-19 | Onxeo | A dbait molecule against acquired resistance in the treatment of cancer |
| CN110272419A (zh) * | 2018-03-14 | 2019-09-24 | 上海艾力斯医药科技有限公司 | 二氢吡啶并酞嗪酮衍生物、其制备方法及应用 |
| WO2019207596A1 (en) | 2018-04-25 | 2019-10-31 | Mylan Laboratories Limited | Novel crystalline forms of rucaparib (s)-camsylate salt and rucaparib free base |
| CN108743557A (zh) * | 2018-06-27 | 2018-11-06 | 李莉 | 一种磷酸瑞卡帕布软胶囊及其制备方法 |
| CN108976236B (zh) * | 2018-08-16 | 2020-11-10 | 湖南华腾制药有限公司 | 一种氘代parp抑制剂、其盐、其制备方法及用途 |
| AU2019373416A1 (en) | 2018-10-30 | 2021-06-10 | Repare Therapeutics Inc. | Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as ATR kinase inhibitors |
| CN111217818A (zh) * | 2018-11-27 | 2020-06-02 | 台耀化学股份有限公司 | 芦卡帕尼樟脑磺酸盐的结晶、及制备三环化合物、芦卡帕尼及其樟脑磺酸盐结晶的方法 |
| CN113365998B (zh) * | 2019-02-02 | 2023-04-14 | 正大天晴药业集团股份有限公司 | 用于parp抑制剂的吲哚并七元酰肟类似物 |
| JP7370032B2 (ja) | 2019-05-14 | 2023-10-27 | スーヂョウ フォー ヘルス ファーマスーティカルズ カンパニー リミテッド | Ｐａｒｒ阻害剤としてのキナゾリン―２．４―ジオン誘導体 |
| CN110256468B (zh) * | 2019-05-14 | 2020-09-01 | 山东省分析测试中心 | 双吲哚生物碱化合物或其药学上可接受的盐及其制备方法和应用 |
| MX2022000449A (es) | 2019-07-10 | 2022-04-25 | Cybrexa 2 Inc | Conjugados peptídicos de citotoxinas como terapéuticos. |
| US11555019B2 (en) | 2019-07-10 | 2023-01-17 | Cybrexa 3, Inc. | Peptide conjugates of microtubule-targeting agents as therapeutics |
| CN114072410B (zh) * | 2019-08-01 | 2023-08-01 | 正大天晴药业集团股份有限公司 | 作为parp抑制剂吲哚并七元酰肟化合物 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| WO2021156140A1 (en) | 2020-02-03 | 2021-08-12 | Sandoz Ag | Polymorph of rucaparib mesylate |
| CA3169303A1 (en) | 2020-02-24 | 2021-09-02 | Xiaokun SHEN | Application of poly adp-ribose polymerase inhibitors in corona virus resistance |
| US20230234938A1 (en) | 2020-04-28 | 2023-07-27 | Rhizen Pharmaceuticals Ag | Novel compounds useful as poly(adp-ribose) polymerase (parp) inhibitors |
| CN111646990B (zh) * | 2020-05-22 | 2023-01-10 | 同济大学 | 一种3,4-桥环吲哚类化合物的制备方法及Rucaparib的合成方法 |
| CN111662299B (zh) * | 2020-07-10 | 2022-07-26 | 中山大学 | 一种取代吲哚并氮杂酮类化合物及其制备方法和应用 |
| EP4182318B1 (en) | 2020-07-14 | 2025-08-27 | Assia Chemical Industries Ltd. | Solid state forms of rucaparib salts |
| AU2021318572A1 (en) * | 2020-07-31 | 2023-02-16 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Indolo heptamyl oxime analog crystal as PARP inhibitor and method for preparing same |
| CN111961047A (zh) * | 2020-08-19 | 2020-11-20 | 南通大学 | 一种6-乙氧基-3,4-二氢-2,7-萘啶-1（2h）-酮及其合成方法 |
| WO2022090938A1 (en) | 2020-10-31 | 2022-05-05 | Rhizen Pharmaceuticals Ag | Phthalazinone derivatives useful as parp inhibitors |
| CN116940691A (zh) | 2021-01-08 | 2023-10-24 | 赛博克萨2公司 | 用于制备缀合物连接部分的方法 |
| WO2022155172A1 (en) | 2021-01-13 | 2022-07-21 | Cybrexa 3, Inc. | Peptide conjugates of therapeutics |
| CA3214298A1 (en) | 2021-04-08 | 2022-10-13 | Swaroop Kumar Venkata Satya VAKKALANKA | Inhibitors of poly(adp-ribose) polymerase |
| MX2023013624A (es) * | 2021-05-18 | 2023-11-30 | Onconic Therapeutics Inc | Forma cristalina del compuesto derivado triciclico, metodo para preparar la misma y composicion farmaceutica que comprende la misma. |
| EP4463232A1 (en) | 2022-01-11 | 2024-11-20 | Assia Chemical Industries Ltd. | Solid state forms of rucaparib tosylate |
| WO2023201338A1 (en) | 2022-04-15 | 2023-10-19 | Ideaya Biosciences, Inc. | Combination therapy comprising a mat2a inhibitor and a parp inhibitor |
| CA3257870A1 (en) | 2022-06-01 | 2023-12-07 | Ideaya Biosciences, Inc. | THIADIAZOLYL DERIVATIVES USED AS DNA POLYMERASE THETA INHIBITORS AND THEIR USES |
| CN121398822A (zh) | 2023-06-21 | 2026-01-23 | 四方生物科学有限公司 | 用于在治疗hr功能正常的癌症的方法中的用途的包含脱氧胞苷衍生物和parp抑制剂的组合 |
| EP4731630A1 (en) * | 2023-06-21 | 2026-04-29 | Valo Health, Inc. | Homophthalazinone indole parp inhibitors and methods of use |
| US12383633B1 (en) * | 2024-10-01 | 2025-08-12 | Zymeron Corporation | Injectable formulations of PARP inhibitors and uses thereof |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3642820A (en) | 1969-11-03 | 1972-02-15 | Upjohn Co | 4 5-dihydropyrrolo(3 2 1-jk)(1 4)bezodiazepines |
| US3883590A (en) | 1971-06-01 | 1975-05-13 | Universal Oil Prod Co | Preparation of n-alkylarylcarboxamides |
| DE2322434A1 (de) | 1973-05-04 | 1974-11-21 | Bayer Ag | 2-trifluormethylimino-1,3-dithioloeckige klammer auf 4,5-b eckige klammer zu -chinoxaline, verfahren zu ihrer herstellung, sowie ihre verwendung als insektizide, akarizide und fungizide |
| US4033960A (en) | 1973-07-31 | 1977-07-05 | Bayer Aktiengesellschaft | 2-Mercaptoquinoxaline-di-N-oxide products and a method for their preparation |
| US3978066A (en) | 1973-11-06 | 1976-08-31 | Ayerst, Mckenna And Harrison Ltd. | Certain 4,6-dihydropyrrolotriazoline-quinoline derivatives |
| US3900477A (en) * | 1973-11-06 | 1975-08-19 | Ayerst Mckenna & Harrison | 5-amino-and 5-hydrazinodihydropyrroloisoquinoline derivatives |
| US3950343A (en) | 1973-11-06 | 1976-04-13 | Ayerst, Mckenna And Harrison Ltd. | Pyrroloisoquinoline derivatives |
| US3959343A (en) * | 1974-10-25 | 1976-05-25 | Wako Pure Chemical Industries, Ltd. | Process for producing hydrazonitriles |
| DE2913728A1 (de) | 1979-04-05 | 1980-10-16 | Bayer Ag | 2-sulfonyl-chinoxaline, verfahren zu ihrer herstellung sowie ihre verwendung als mikrobizide |
| DE3103137A1 (de) | 1981-01-30 | 1982-08-26 | Bayer Ag, 5090 Leverkusen | Verfahren zur herstellung aliphatischer cyclischer kohlensaeureester |
| JPS57144286A (en) | 1981-03-02 | 1982-09-06 | Takeda Chem Ind Ltd | Azepinoindole derivative and its preparation |
| US5215738A (en) | 1985-05-03 | 1993-06-01 | Sri International | Benzamide and nicotinamide radiosensitizers |
| US4910193A (en) | 1985-12-16 | 1990-03-20 | Sandoz Ltd. | Treatment of gastrointestinal disorders |
| JPS6434988A (en) * | 1987-07-30 | 1989-02-06 | Kissei Pharmaceutical | Azepinoindole derivative |
| DE4125292A1 (de) * | 1991-07-31 | 1993-02-04 | Kali Chemie Pharma Gmbh | 6-oxo-azepinoindol-verbindungen sowie verfahren und zwischenprodukte zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
| GB9117987D0 (en) | 1991-08-20 | 1991-10-09 | Ici Plc | Heterocyclic compounds |
| US5342946A (en) | 1992-12-02 | 1994-08-30 | Guilford Pharmaceuticals Inc. | Phosphonoalkylquinolin-2-ones as novel antagonists of non-NMDA ionotropic excitatory amino acid receptors |
| WO1995009159A1 (en) | 1993-09-28 | 1995-04-06 | Otsuka Pharmaceutical Company, Limited | Quinoxaline derivative as antidiabetic agent |
| US5587384A (en) | 1994-02-04 | 1996-12-24 | The Johns Hopkins University | Inhibitors of poly(ADP-ribose) synthetase and use thereof to treat NMDA neurotoxicity |
| GB9404485D0 (en) | 1994-03-09 | 1994-04-20 | Cancer Res Campaign Tech | Benzamide analogues |
| US5561161A (en) | 1994-03-25 | 1996-10-01 | Oxigene, Inc. | Methods of administering and pharmaceutical formulations containing n-substituted benzamides and/or acid addition salts thereof |
| US5589483A (en) | 1994-12-21 | 1996-12-31 | Geron Corporation | Isoquinoline poly (ADP-ribose) polymerase inhibitors to treat skin diseases associated with cellular senescence |
| ES2105959B1 (es) | 1995-01-17 | 1998-07-01 | Zeneca Pharma Sa | Derivados de 1,4-dioxido de quinoxalina, procedimiento de preparacion y de utilizacion. |
| US5756548A (en) | 1995-04-03 | 1998-05-26 | Centaur Pharmaceuticals, Inc. | Acetamidobenzamide compounds for neurodegenerative disorders |
| US5659082A (en) | 1995-04-03 | 1997-08-19 | Centaur Pharmaceuticals, Inc. | Nitro- and aminobenzamide compounds for neurodegenerative disorders |
| EP0841924B1 (en) * | 1995-08-02 | 2002-10-02 | Newcastle University Ventures Limited | Benzimidazole compounds |
| HUT76302A (en) | 1995-11-30 | 1997-07-28 | Chinoin Gyogyszer Es Vegyeszet | Quinoxaline derivatives, pharmaceutical compositions containing them and process for producing them |
| US6028111A (en) | 1996-03-08 | 2000-02-22 | Oxigene, Inc. | Compositions and use of benzamides and nicotinamides as anti-inflammatory agents |
| GB9702701D0 (en) | 1997-02-01 | 1997-04-02 | Univ Newcastle Ventures Ltd | Quinazolinone compounds |
| AU7484798A (en) | 1997-05-13 | 1998-12-08 | Octamer, Inc. | Methods for treating inflammation, inflammatory diseases, arthritis and strok e using padprt inhibitors |
| US6197785B1 (en) | 1997-09-03 | 2001-03-06 | Guilford Pharmaceuticals Inc. | Alkoxy-substituted compounds, methods, and compositions for inhibiting PARP activity |
| US6635642B1 (en) | 1997-09-03 | 2003-10-21 | Guilford Pharmaceuticals Inc. | PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same |
| WO1999011622A1 (en) | 1997-09-03 | 1999-03-11 | Guilford Pharmaceuticals Inc. | Amino-substituted compounds, methods, and compositions for inhibiting parp activity |
| US6514983B1 (en) | 1997-09-03 | 2003-02-04 | Guilford Pharmaceuticals Inc. | Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage |
| WO1999011644A1 (en) | 1997-09-03 | 1999-03-11 | Guilford Pharmaceuticals Inc. | Di-n-heterocyclic compounds, methods, and compositions for inhibiting parp activity |
| US20020022636A1 (en) | 1997-09-03 | 2002-02-21 | Jia-He Li | Oxo-substituted compounds, process of making, and compositions and methods for inhibiting parp activity |
| US20020028813A1 (en) | 1997-09-03 | 2002-03-07 | Paul F. Jackson | Thioalkyl compounds, methods, and compositions for inhibiting parp activity |
| CA2332279A1 (en) | 1998-05-15 | 1999-11-25 | Jia-He Li | Carboxamide compounds, compositions, and methods for inhibiting parp activity |
| AU9298798A (en) * | 1998-05-15 | 1999-12-06 | Guilford Pharmaceuticals Inc. | Fused tricyclic compounds which inhibit parp activity |
| EP1183259A2 (de) | 1999-09-28 | 2002-03-06 | Basf Aktiengesellschaft | Azepinoindol-derivate, deren herstellung und anwendung |
| DE19946289A1 (de) | 1999-09-28 | 2001-03-29 | Basf Ag | Benzodiazepin-Derivate, deren Herstellung und Anwendung |
-
2000
- 2000-01-10 US US09/479,896 patent/US6495541B1/en not_active Expired - Lifetime
- 2000-01-10 RS YUP-490/01A patent/RS50031B/sr unknown
- 2000-01-10 AP APAP/P/2001/002211A patent/AP1538A/en active
- 2000-01-10 HR HR20010573A patent/HRP20010573B1/xx not_active IP Right Cessation
- 2000-01-10 NZ NZ512731A patent/NZ512731A/xx not_active IP Right Cessation
- 2000-01-10 BR BRPI0008614A patent/BRPI0008614B8/pt not_active IP Right Cessation
- 2000-01-10 CA CA2360003A patent/CA2360003C/en not_active Expired - Lifetime
- 2000-01-10 DE DE60009033T patent/DE60009033T2/de not_active Expired - Lifetime
- 2000-01-10 GE GEAP20006045A patent/GEP20033055B/en unknown
- 2000-01-10 OA OA1200100183A patent/OA11749A/en unknown
- 2000-01-10 EP EP00902358A patent/EP1140936B1/en not_active Expired - Lifetime
- 2000-01-10 WO PCT/US2000/000411 patent/WO2000042040A1/en not_active Ceased
- 2000-01-10 PL PL357049A patent/PL210415B1/pl unknown
- 2000-01-10 DK DK00902358T patent/DK1140936T3/da active
- 2000-01-10 KR KR1020017008709A patent/KR100632079B1/ko not_active Expired - Lifetime
- 2000-01-10 IL IL14411200A patent/IL144112A0/xx active IP Right Grant
- 2000-01-10 SK SK966-2001A patent/SK287338B6/sk not_active IP Right Cessation
- 2000-01-10 MX MXPA01007001A patent/MXPA01007001A/es active IP Right Grant
- 2000-01-10 AU AU24088/00A patent/AU781711B2/en not_active Expired
- 2000-01-10 ES ES00902358T patent/ES2218110T3/es not_active Expired - Lifetime
- 2000-01-10 TR TR2001/02005T patent/TR200102005T2/xx unknown
- 2000-01-10 HU HU0105414A patent/HU229875B1/hu unknown
- 2000-01-10 RO ROA200100795A patent/RO121778B1/ro unknown
- 2000-01-10 AT AT00902358T patent/ATE261963T1/de active
- 2000-01-10 SI SI200020013A patent/SI20691B/sl active Search and Examination
- 2000-01-10 CN CNB008045895A patent/CN100418967C/zh not_active Expired - Lifetime
- 2000-01-10 EA EA200100764A patent/EA004989B1/ru not_active IP Right Cessation
- 2000-01-10 CZ CZ20012443A patent/CZ302941B6/cs not_active IP Right Cessation
- 2000-01-10 PT PT00902358T patent/PT1140936E/pt unknown
- 2000-01-10 EE EEP200100364A patent/EE05006B1/xx unknown
- 2000-01-10 JP JP2000593608A patent/JP4093448B2/ja not_active Expired - Lifetime
- 2000-01-19 ID IDW00200101726A patent/ID30138A/id unknown
- 2000-10-01 UA UA2001074881A patent/UA75034C2/uk unknown
-
2001
- 2001-06-29 ZA ZA200105399A patent/ZA200105399B/en unknown
- 2001-07-02 IL IL144112A patent/IL144112A/en not_active IP Right Cessation
- 2001-07-04 NO NO20013313A patent/NO320343B1/no not_active IP Right Cessation
- 2001-07-10 IS IS5995A patent/IS5995A/is unknown
- 2001-08-01 LV LV010115A patent/LV12770B/xx unknown
- 2001-08-10 BG BG105811A patent/BG65210B1/bg unknown
- 2001-08-10 LT LT2001083A patent/LT4936B/lt not_active IP Right Cessation
-
2002
- 2002-08-28 OA OA1200200262A patent/OA12185A/en unknown
- 2002-10-02 US US10/264,018 patent/US20030078254A1/en not_active Abandoned
-
2004
- 2004-12-03 US US11/004,261 patent/US6977298B2/en not_active Expired - Lifetime
-
2005
- 2005-09-06 US US11/221,245 patent/US7429578B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI20691B (sl) | Triciklični inhibitorji poli(ADP-riboza) polimeraz | |
| AR064608A1 (es) | Derivados de pirazolo-quinazolina sustituidos, composiciones farmaceuticas que los contienen. proceso para su preparacion y uso de los mismos como agentes anticancer. | |
| AR046297A1 (es) | Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo | |
| AR010378A1 (es) | Novedosos compuestos con efecto analgesico, uso de los mismos para la preparacion de un medicamento y como agente de diagnostico, composicion farmaceutica, proceso para la preparacion de dichos compuestos y compuestos intermediarios | |
| JP2009536620A5 (https=) | ||
| ME02855B (me) | KONDENZOVANI TETRA ILl PENTA-CIKLIČNI DIHIDRODIAZEPINOKARBAZOLONI KAO PARP INHIBITORI | |
| BR0113838A (pt) | Derivados de n-fenil-2-pirimidina-amina | |
| RU2012117829A (ru) | Фосфорамидатные производные нуклеозидов | |
| JP2013523614A5 (https=) | ||
| AR069666A1 (es) | Derivados de imidazo[1, 2 - a]piridina e imidazo[1, 2 -b]piridazina, una composicion farmaceutica que los contiene y su uso en la preparacion de un medicamento para el tratamiento de enfermedades mediadas por las celulas b. | |
| CY1113538T1 (el) | Παραγωγα της 5-αμινο-2,4,7-τριοξο-3,4,7,8-τετραϋδρο-2η-πυριδο[2,3-d] πυριμιδινης και παρομοιες ενωσεις για την αγωγη του καρκινου | |
| AR022860A1 (es) | Derivados de camptotecina que poseen actividad antitumoral | |
| RU2016118753A (ru) | Производные пиридилкетона, способ их получения и их фармацевтическое применение | |
| RU2009144538A (ru) | Новые циклические пептидные соединения | |
| MY137156A (en) | Dual nk1/nk3 derivatives | |
| AR043658A1 (es) | Derivados 8-substituidos-6,7,8,9-tetrahidropirimido[1,2-a]pirimidin-4-ona | |
| ATE530187T1 (de) | Pharmazeutische zubereitungen mit nk1-rezeptor- antagonisten und natriumkanalblockern | |
| EA200970705A1 (ru) | Новые фармацевтические композиции | |
| ATE311378T1 (de) | Benzopyran derivate | |
| EP0765865A4 (en) | 2-ACYLAMINOPROPANOL COMPOUND AND MEDICINAL COMPOSITION | |
| TW200619197A (en) | Compounds which potentiate glutamate receptor and uses thereof in medicine | |
| JP2013511526A5 (https=) | ||
| CY1105780T1 (el) | Ετepο-δικυκλικοi crf ανταγωνιστeς | |
| CA2487252A1 (en) | Esters in position 20 of camptothecins | |
| AR053364A1 (es) | Compuesto de 1h-imidazo 84,5-c) piridin -2- ilo, composicion farmaceutica que lo comprende, proceso para prepararla y su uso para preparar un medicamento para tratamiento de cancer o artritis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| IF | Valid on the event date | ||
| SP73 | Change of data on owner |
Owner name: AGOURON PHARMACEUTICALS, INC.; GB Effective date: 20080429 |
|
| OU02 | Decision according to article 73(2) ipa 1992, publication of decision on partial fulfilment of the invention and change of patent claims |
Effective date: 20080903 |